1. A double‐blind, randomized, placebo‐controlled phase 2 trial evaluating the selective dihydroorotate dehydrogenase inhibitor vidofludimus calcium in relapsing‐remitting multiple sclerosis. Issue 7 (14th June 2022) Authors: Fox, Robert J.; Wiendl, Heinz; Wolf, Christian; De Stefano, Nicola; Sellner, Johann; Gryb, Viktoriia; Rejdak, Konrad; Bozhinov, Plamen Stoyanov; Tomakh, Nataliya; Skrypchenko, Iryna; Muehler, Andreas R. Journal: Annals of clinical and translational neurology Issue: Volume 9:Issue 7(2022) Page Start: 977 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Risk for Major Bleeding in Patients Receiving Ticagrelor Compared With Aspirin After Transient Ischemic Attack or Acute Ischemic Stroke in the SOCRATES Study (Acute Stroke or Transient Ischemic Attack Treated With Aspirin or Ticagrelor and Patient Outcomes). Issue 10 (5th September 2017) Authors: Easton, J. Donald; Aunes, Maria; Albers, Gregory W.; Amarenco, Pierre; Bokelund-Singh, Sara; Denison, Hans; Evans, Scott R.; Held, Peter; Jahreskog, Marianne; Jonasson, Jenny; Minematsu, Kazuo; Molina, Carlos A.; Wang, Yongjun; Wong, K.S. Lawrence; Johnston, S. Claiborne; Ameriso, Sebastiá F.; Do... Journal: Circulation Issue: Volume 136:Issue 10(2017) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗